nach oben

Erschienen in:

01.05.2012 | Review Article

Patent Ductus Arteriosus in Premature Neonates

Erschienen in: Drugs | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Persistent patency of the ductus arteriosus is a major cause of morbidity and mortality in premature infants. In infants born prior to 28 weeks of gestation, a haemodynamically significant patent ductus arteriosus (PDA) can cause cardiovascular instability, exacerbate respiratory distress syndrome, prolong the need for assisted ventilation and increase the risk of bronchopulmonary dysplasia, intraventricular haemorrhage, renal dysfunction, cerebral palsy and mortality. We review the pathophysiology, clinical features and assessment of haemodynamic significance, and provide a rigorous appraisal of the quality of evidence to support current medical and surgical management of PDA of prematurity. Cyclo-oxygenase inhibitors such as indomethacin and ibuprofen remain the mainstay of medical therapy for PDA, and can be used both for prophylaxis as well as for rescue therapy to achieve PDA closure. Surgical ligation is also effective and is used in infants who do not respond to medical management. Although both medical and surgical treatment have proven efficacy in closing the ductus, both modalities are associated with significant adverse effects. Because the ductus does undergo spontaneous closure in some premature infants, improved and early identification of infants most likely to develop a symptomatic PDA could help in directing treatment to the at-risk infants and allow others to receive expectant management.

Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics 2010; 125 (5): 1020–30PubMedCrossRef

Yokoyama U, Minamisawa S, Ishikawa Y. Regulation of vascular tone and remodeling of the ductus arteriosus. J Smooth Muscle Res 2010; 46 (2): 77–87PubMedCrossRef

Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 2001; 107 (1): E1

Koch J, Hensley G, Roy L, et al. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006; 117 (4): 1113–21PubMedCrossRef

Richards J, Johnson A, Campbell M. A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants. Pediatrics 2009; 124 (2): e287-93

Kozik D, Ivy D, Ibrahim J, et al. Patent ductus arteriosus. In: Munoz R, Morell V, Cruz ED, et al., editors. Critical care of children with heart disease. London: Springer Verlag, 2010: 145-57

Furzan JA, Reisch J, Tyson JE, et al. Incidence and risk factors for symptomatic patent ductus arteriosus among inborn very-low-birth-weight infants. Early Hum Dev 1985; 12 (1): 39–48PubMedCrossRef

Mouzinho AI, Rosenfeld CR, Risser R. Symptomatic patent ductus arteriosus in very-low-birth-weight infants: 1987-1989. Early Hum Dev 1991; 27 (1-2): 65-77

Jones RW, Pickering D. Persistent ductus arteriosus complicating the respiratory distress syndrome. Arch Dis Child 1977; 52 (4): 274–81PubMedCrossRef

10.

Fowlie PW, Davis PG. Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2003; 88 (6): F464-6

11.

Behman RE, Jacob J, Gluck L, et al. The contribution of PDA in the neonate with severe RDS. J Pediatr 1980; 96 (1): 79–87CrossRef

12.

Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2010; (7): CD000174

13.

Kluckow M, Evans N. Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage. J Pediatr 2000; 137 (1): 68–72PubMedCrossRef

14.

Finlay ER, Subhedar NV. Pulmonary haemorrhage in preterm infants. Eur J Pediatr 2000; 159 (11): 870–1PubMedCrossRef

15.

Siassi B, Emmanouilides GC, Cleveland RJ, et al. Patent ductus arteriosus complicating prolonged assisted ventilation in respiratory distress syndrome. J Pediatr 1969; 74 (1): 11–9PubMedCrossRef

16.

Oh W, Poindexter BB, Perritt R, et al. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr 2005; 147 (6): 786–90PubMedCrossRef

17.

Redline RW, Wilson-Costello D, Hack M. Placental and other perinatal risk factors for chronic lung disease in very low birth weight infants. Pediatr Res 2002; 52 (5): 713–9PubMedCrossRef

18.

Marshall DD, Kotelchuck M, Young TE, et al. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association. Pediatrics 1999; 104 (6): 1345–50

19.

Kitterman JA, Edmunds HL, Gregory GA, et al. Patent ducts arteriosus in premature infants: incidence, relation to pulmonary disease and management. N Engl J Med 1972; 287 (10): 473–7PubMedCrossRef

20.

Northway Jr WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967; 276 (7): 357–68CrossRef

21.

Dykes FD, Lazara A, Ahmann P, et al. Intraventricular hemorrhage: a prospective evaluation of etiopathogen-esis. Pediatrics 1980; 66 (1): 42–9PubMed

22.

Evans N, Kluckow M. Early ductal shunting and in-traventricular haemorrhage in ventilated preterm infants. Arch Dis Child Fetal Neonatal Ed 1996; 75 (3): F183-6

23.

Vanpee M, Ergander U, Herin P, et al. Renal function in sick, very low-birth-weight infants. Acta Paediatr 1993; 82 (9): 714–8PubMedCrossRef

24.

Dollberg S, Lusky A, Reichman B. Patent ductus arte-riosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. J Pediatr Gastroenterol Nutr 2005; 40 (2): 184–8PubMedCrossRef

25.

Ryder RW, Shelton JD, Guinan ME. Necrotizing enterocolitis: a prospective multicenter investigation. Am J Epidemiol 1980; 112 (1): 113–23PubMed

26.

Shortland DB, Gibson NA, Levene MI, et al. Patent ductus arteriosus and cerebral circulation in preterm infants. Dev Med Child Neurol 1990; 32 (5): 386–93PubMedCrossRef

27.

Drougia A, Giapros V, Krallis N, et al. Incidence and risk factors for cerebral palsy in infants with perinatal problems: a 15-year review. Early Hum Dev 2007; 83 (8): 541–7PubMedCrossRef

28.

Noori S, McCoy M, Friedlich P, et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics 2009; 123 (1): e138-44

29.

Brooks J, Travadi J, Patole S, et al. Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management. Arch Dis Child Fetal Neonatal Ed 2005; 90 (3): F235-9

30.

Rojas MA, Gonzalez A, Bancalari E, et al. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995; 126 (4): 605–10PubMedCrossRef

31.

Chiruvolu A, Jaleel MA. Pathophysiology of patent ductus arteriosus in premature neonates. Early Hum Dev 2009; 85 (3): 143–6PubMedCrossRef

32.

Clyman RI. Mechanisms regulating the ductus arteriosus. Biol Neonate 2006; 89 (4): 330–5PubMedCrossRef

33.

Heymann MA, Rudolph AM. Control of the ductus arteriosus. Physiol Rev 1975; 55 (1): 62–78PubMed

34.

Chiruvolu A, Punjwani P, Ramaciotti C. Clinical and echocardiographic diagnosis of patent ductus arteriosus in premature neonates. Early Hum Dev 2009; 85 (3): 147–9PubMedCrossRef

35.

Cotton RB, Lindstrom DP, Stahlman MT. Early prediction of symptomatic patent ductus arteriosus from perinatal risk factors: a discriminant analysis model. Acta Paediatr Scand 1981; 70 (5): 723–7PubMedCrossRef

36.

Clyman RI. Ibuprofen and patent ductus arteriosus. N Engl J Med 2000; 343 (10): 728–30PubMedCrossRef

37.

Yeh TF. Patent ductus arteriosus in preterm infants. HK J Paediatr 1997; 2: 9–17

38.

Yeh TF, Raval D, Luken J, et al. Clinical evaluation of premature infants with patent ductus arteriosus: a scoring system with echocardiogram, acid-base, and blood gas correlations. Crit Care Med 1981; 9 (9): 655–7PubMedCrossRef

39.

Wald RM, Adatia I, Van Arsdell GS, et al. Relation of limiting ductal patency to survival in neonatal Ebstein’s anomaly. Am J Cardiol 2005; 96 (6): 851–6PubMedCrossRef

40.

Iyer P, Evans N. Re-evaluation of the left atrial to aortic root ratio as a marker of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed, 1994; 70 (2): F112-7

41.

Ramos FG, Rosenfeld CR, Roy L, et al. Echocardio-graphic predictors of symptomatic patent ductus arte-riosus in extremely-low-birth-weight preterm neonates. J Perinatol 2010; 30 (8): 535–9PubMedCrossRef

42.

Sanjeev S, Pettersen M, Lua J, et al. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol 2005; 25 (11): 709–13PubMedCrossRef

43.

Choi BM, Lee KH, Eun LB, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005; 115 (3): e255-61

44.

Patel J, Roberts I, Azzopardi D, et al. Randomized doubleblind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res 2000; 47 (1): 36–42PubMedCrossRef

45.

Knight DB. The treatment of patent ductus arteriosus in preterm infants: a review and overview of randomized trials. Semin Neonatol 2001; 6 (1): 63–73PubMedCrossRef

46.

Ohlsson A, Shah SS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2011; (7): CD004213

47.

Cotton RB, Stahlman MT, Kovar I, et al. Medical management of small preterm infants with symptomatic patent ductus arteriosus. J Pediatr 1978; 92 (3): 467–73PubMedCrossRef

48.

Mahony L, Carnero V, Brett C, et al. Prophylactic indo-methacin therapy for patent ductus arteriosus in very-low-birth-weight infants. N Engl J Med 1982; 306 (9): 506–10PubMedCrossRef

49.

Weesner KM, Dillard RG, Boyle RJ, et al. Prophylactic treatment of asymptomatic patent ductus arteriosus in premature infants with respiratory distress syndrome. South Med J 1987; 80 (6): 706–8PubMedCrossRef

50.

Hammerman C, Startes E, Komark K, et al. Failure of prophylactic indomethacin to improve the outcome of the very low birth weight infant. Dev Pharmacol Ther 1987; 10 (6): 393–404PubMed

51.

Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2010; (4): CD003481

52.

Gokmen T, Erdeve O, Altug N, et al. Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus. J Pediatr 2011; 158 (4): 549–54 e1PubMedCrossRef

53.

Koehne PS, Bein G, Alexi-Mekhishvili V, et al. Patent ductus arteriosus in very low birthweight infants: complications of pharmacological and surgical treatment. J Perinat Med 2001; 29 (4): 327–34PubMedCrossRef

54.

Palder SB, Schwartz MZ, Tyson KRT, et al. Management of patent ductus arteriosus: a comparison of operative v pharmacologic treatment. J Pediatr Surg 1987; 22 (12): 1171–4PubMedCrossRef

55.

Pokharel R, Hisano K, Yasufuku M, et al. Ligation of medically refracted patent ductus arteriosus (PDA) in an extremely low body weight premature infant. Surg Today 1998; 28 (12): 1290–4PubMedCrossRef

56.

Satur CR, Walker DR, Dickinson DF. Day case ligation of patent ductus arteriosus in preterm infants: a 10 year review. Arch Dis Child 1991; 66 (4): 477–80PubMedCrossRef

57.

Chen KB, Cheng HC, Wu YL, et al. The anesthetic management of a preterm infant weighing 500 grams undergoing ligation of patent ductus arteriosus: a case report. Acta Anaesthesiol Sin 1999; 37 (2): 89–92PubMed

58.

Trus T, Winthrop AL, Pipe S, et al. Optimal management of patent ductus arteriosus in the neonate weighing less than 800 g. J Pediatr Surg 1993; 28 (9): 1137–9PubMedCrossRef

59.

Naulty CM, Horn S, Conry J, et al. Improved lung compliance after ligation of patent ductus arteriosus in hyaline membrane disease. J Pediatr 1978; 93 (4): 682–4PubMedCrossRef

60.

Mosalli R, Alfaleh K. Prophylactic surgical ligation of patent ductus arteriosus for prevention of mortality and morbidity in extremely low birth weight infants. Cochrane Database Syst Rev 2008; (1): CD006181

61.

Mikhail M, Lee W, Toews W, et al. Surgical and medical experience with 734 premature infants with patient ductus arteriosus. J Thorac Cardiovasc Surg 1982; 83 (3): 349–57PubMed

62.

Zbar RI, Chen AH, Behrendt DM, et al. Incidence of vocal fold paralysis in infants undergoing ligation of patent ductus arteriosus. Ann Thorac Surg 1996; 61 (3): 814–6PubMedCrossRef

63.

Gersony WM, Peckman GJ, Ellison RC, et al. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983; 102 (6): 895–906PubMedCrossRef

64.

Chorne N, Leonard C, Piecuch R, et al. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics 2007; 119 (6): 1165–74PubMedCrossRef

65.

Kabra NS, Schmidt B, Roberts RS, et al. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr 2007; 150 (3): 229–34, 234 e1PubMedCrossRef

66.

Raval MV, Laughon MM, Bose CL, et al. Patent ductus arteriosus ligation in premature infants: who really benefits, and at what cost?. J Pediatr Surg 2007; 42 (1): 69–75; discussion 75PubMedCrossRef

67.

Rao R, Bryowsky K, Mao K, et al. Gastrointestinal complications associated with ibuprofen therapy for patent ductus arteriosus. J Perinatol 2011 Jul; 31 (7): 465–70PubMedCrossRef

68.

Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2008; (1): CD003481

69.

Lee SK, McMillan DD, Ohlsson A, et al. Variations in practice and outcomes in the Canadian NICU network: 1996-1997. Pediatrics 2000; 106 (5): 1070–9PubMedCrossRef

70.

Sperandio M, Beedgen B, Feneberg R, et al. Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation. Pediatrics 2005; 116 (6): 1361–6PubMedCrossRef

71.

Chorne N, Jegatheesan P, Lin E, et al. Risk factors for persistent ductus arteriosus patency during indomethacin treatment. J Pediatr 2007; 151 (6): 629–34PubMedCrossRef

72.

Jegatheesan P, Ianus V, Buchh B, et al. Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized, controlled trial. J Pediatr 2008; 153 (2): 183–9PubMedCrossRef

73.

Bandstra ES, Montalvo BM, Goldberg RN, et al. Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants. Pediatrics 1988; 82 (4): 533–42PubMed

74.

Couser RJ, Ferrara B, Wright GB, et al. Prophylactic indomethacin therapy in the first twenty-four hours of life for the prevention of patent ductus arteriosus in preterm infants treated prophylactically with surfactant in the delivery room. J Pediatr 1996; 128 (5 Pt 1): 631-7

75.

Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001; 344 (26): 1966–72PubMedCrossRef

76.

Domanico RS, Waldman JD, Lester LA, et al. Prophylactic indomethacin reduces the incidence of pulmonary hemorrhage and patent ductus arteriosus in surfactant-treated infants <1250 grams [abstract]. Pediatr Res 1994; 35: 331A

77.

Alfaleh K, Smyth JA, Roberts RS. Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms. Pediatrics 2008; 121 (2): e233-8

78.

Cooke L, Steer P, Woodgate P. Indomethacin for asymptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev 2003; (2): CD003745

79.

Keller RL, Clyman RI. Persistent Doppler flow predicts lack of response to multiple courses of indomethacin in premature infants with recurrent patent ductus arteriosus. Pediatrics 2003; 112 (3 Pt 1): 583-7

80.

Weiss H, Cooper B, Brook M, et al. Factors determining reopening of the ductus arteriosus after successful clinical closure with indomethacin. J Pediatr 1995; 127 (3): 466–71PubMedCrossRef

81.

Little DC, Pratt TC, Blalock SE, et al. Patent ductus arteriosus in micropreemies and full-term infants: the relative merits of surgical ligation versus indomethacin treatment. J Pediatr Surg 2003; 38 (3): 492–6PubMedCrossRef

82.

Rosito G, Sum K, Chorne N. Comparison of two neonatal indomethacin protocols: efficacy and outcome for patent ductus arteriosus closure. J Clin Pharm Ther 2010; 35 (5): 589–92PubMedCrossRef

83.

Yoshimoto S, Sakai H, Ueda M, et al. Prophylactic indomethacin in extremely premature infants between 23 and 24 weeks gestation. Pediatr Int 2010; 52 (3): 374–7PubMedCrossRef

84.

Gork AS, Ehrenkranz RA, Bracken MB. Continuous infusion versus intermittent bolus doses of indomethacin for patent ductus arteriosus closure in symptomatic preterm infants. Cochrane Database Syst Rev 2008; (1): CD006071

85.

Christmann V, Liem KD, Semmekrot BA, et al. Changes in cerebral, renal and mesenteric blood flow velocity during continuous and bolus infusion of indomethacin. Acta Paediatr 2002; 91 (4): 440–6PubMedCrossRef

86.

Sangtawesin C, Sangtawesin V, Lertsuthiwong W, et al. Prophylaxis of symptomatic patent ductus arteriosus with oral ibuprofen in very low birth weight infants. J Med Assoc Thai 2008; 91 Suppl. 3: S28–34PubMed

87.

Sangtawesin V, Sangtawesin C, Raksasinborisut C, et al. Oral ibuprofen prophylaxis for symptomatic patent ductus arteriosus of prematurity. J Med Assoc Thai 2006; 89 (3): 314–21PubMed

88.

Jones LJ, Craven PD, Attia J, et al. Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants. Arch Dis Child Fetal Neonatal Ed 2010; 96 (1): F45-52

89.

Adamska E, Helwich E, Rutkowaska M, et al. Comparison of the efficacy of ibuprofen and indomethacin in the treatment of patent ductus arteriosus in prematurely born infants [in Polish]. Med Wieku Rozwoj 2005; 9 (3Pt1): 335-54

90.

Gimeno NA, Cano SA, Fernandez GC. Ibuprofen versus indomethacin in the treatment of patent ductus arteriosus in preterm infants [in Spanish]. An Pediatr (Barc) 2005; 63: 212–8CrossRef

91.

Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr 2002; 161 (4): 202–7PubMedCrossRef

92.

Mosca F, Bray M, Lattanzio M, et al. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr 1997; 131 (4): 549–54PubMedCrossRef

93.

Pezzati M, Vangi V, Biagiotti R, et al. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999; 135 (6): 733–8PubMedCrossRef

94.

Plavka SP, Borek I, Biolek J, et al. Ibuprofen vs. indomethacin in the treatment of patent ductus arteriosus (PDA) in very premature neonates [abstract]. Pediatr Res 2001; 49: 375A

95.

Su PH, Chen JY, Su CM, et al. Comparison of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants. Pediatr Int 2003; 45 (6): 665–70PubMedCrossRef

96.

Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000; 343 (10): 674–81PubMedCrossRef

97.

Van Overmeire B, Follens I, Hartmann S, et al. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child Fetal Neonatal Ed 1997; 76: F179–84PubMedCrossRef

98.

Yeh TF, Luken JA, Thaji A, et al. Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus: a double-blind controlled study. J Pediatr 1981; 98 (1): 137–45PubMedCrossRef

99.

Katakam LI, Cotton MC, Goldberg RN, et al. Safety and effectiveness of indomethacin versus ibuprofen for treatment of patent ductus arteriosus. Am J Perinatol 2010; 27 (5): 425–9PubMedCrossRef

100.

Linder N, Bello R, Hernandez A, et al. Treatment of patent ductus arteriosus: indomethacin or ibuprofen?. Am J Perinatol 2010; 27 (5): 399–404PubMedCrossRef

101.

Cherif A, Khrouf N, Jabnoun S, et al. Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Pediatrics 2008; 122 (6): e1256-61

102.

Chotigeat U, Jirapapa K, Layangkool T. A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. J Med Assoc Thai 2003; 86 Suppl. 3: S563–9PubMed

103.

Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?. J Perinatol 2010; 30 (4): 241–52PubMedCrossRef

104.

Laughon MM, Simmons MA, Bose CL. Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated?. Curr Opin Pediatr 2004; 16 (2): 146–51PubMedCrossRef

105.

Noori S. Patent ductus arteriosus in the preterm infant: to treat or not to treat?. J Perinatol 2010; 30 Suppl.: S31-7

Titel: Patent Ductus Arteriosus in Premature Neonates
Publikationsdatum: 01.05.2012
Erschienen in: Drugs / Ausgabe 7/2012
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/11632870-000000000-00000

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Patent Ductus Arteriosus in Premature Neonates

Abstract

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2012

Dihydroartemisinin/Piperaquine

Bevacizumab in Ovarian Cancer

The Author’s Reply

Coming to Terms with Nonsteroidal Anti-Inflammatory Drug Gastropathy

Pharmacotherapy for Breakthrough Cancer Pain

Sickle Cell Disease in Children